Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May;150(10):555-561.
doi: 10.1055/a-2453-8887. Epub 2025 Apr 22.

[Adjuvant and neoadjuvant therapy of melanoma]

[Article in German]
Dirk Debus, Axel Hauschild, Erwin S Schultz
Review

[Adjuvant and neoadjuvant therapy of melanoma]

[Article in German]
Dirk Debus et al. Dtsch Med Wochenschr. 2025 May.

Abstract

The treatment of malignant melanoma with (neo-)adjuvant therapy represents a promising approach to reducing recurrence and metastasis. At the same time, due to the risk of potential side effects, a risk-benefit assessment is required in advance, taking into account the stage-dependent risk of recurrence. The article presents the current study situation on adjuvant and neoadjuvant therapy.

PubMed Disclaimer

Conflict of interest statement

Dirk Debus: Honorare für Advisory Boards und/oder Übernahme von Fortbildungskosten (BMS, MSD, Novartis, Pierre Fabre, Sanofi, SUN) Axel Hauschild: Unterstützung bei klinischen Studien (Zuwendung an Institution) und/oder persönliche Vortragshonorare und/oder Advisory Boards und/oder Beratungen (BMS, MerckPfizer, MSD/Merck, Philogen, Pierre Fabre, Regeneron, Roche, Sanofi-Genzyme, Novartis, Eisai, Immunocore, Replimune, Seagen, IO Biotech, Dermagnostix, Incyte, NeraCare, Huya Biosciences, Kyowa Kirin, Iovance, Highlight Therapeutics, CureVac, Xenthera, Agenus, Almirall, Sun Pharma) Erwin S. Schultz: Honorare für Advisory Boards (BMS)

LinkOut - more resources